Related Experiment Video
Updated: May 29, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality
Ruyan Rahnama1, Monika Kizerwetter2, Huilin Yang3
1Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Background:
Natural Killer (NK) cells have intrinsic anticancer activity that can be redirected toward acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) engineering. Here, we study the functional consequences of CAR binding affinity and targeted epitope on CAR-NK cell activation, cytolytic synapse formation, and antitumor activity.
Methods:
We characterized NK-92 and primary NK cell populations expressing variant affinity AML-specific CARs containing single-chain variable fragments (scFvs, 26292 or 7G3) targeting two epitopes on CD123. 26292 affinity variants were discovered through directed evolution of an error-prone mutagenic library, while 7G3 affinity variants were previously reported. The resulting CAR-NK cell panel was studied with in vitro binding, activation, and cytotoxicity studies and in mouse xenograft models.
Results:
26292 and 7G3 CARs of variable CD123 binding affinities were highly expressed in NK cells and conferred antigen-specific activation in vitro. High-resolution imaging demonstrated greater clustering of high-affinity 7G3 CAR-NK cells and consequent AML target cell death in a short-term time lapse. Low-affinity 7G3 CAR-NK cells exhibited enhanced antigen density discrimination with greater membrane-proximal signaling, cytokine production, and cytotoxicity. In longer-term assays, low-affinity 7G3 CAR-NK cells demonstrated more sustained killing of AML cells. In vivo testing highlighted greater expansion of low-affinity 7G3 CAR-NK cells in two xenograft models.
Conclusions:
Expression of 26292 and 7G3 CARs with a range of CD123 binding affinities in NK cells leads to antigen-specific activation and cytotoxicity against AML. Affinity-based differences in functional activation and antitumor activity are dependent on time course and are scFv/epitope specific.
Insights
Chimeric antigen receptor (CAR)-NK cells targeting CD123 show potent anti-acute myeloid leukemia (AML) activity. Lower CAR binding affinity enhances NK cell discrimination of antigen density, leading to sustained antitumor effects in AML.
Area of Science:
- Immunology
- Cell Therapy
- Oncology
Background:
- Natural Killer (NK) cells possess inherent anticancer properties.
- Chimeric antigen receptor (CAR) engineering redirects NK cell activity against cancer, including acute myeloid leukemia (AML).
- The impact of CAR binding affinity and epitope targeting on CAR-NK cell function requires further investigation.
Purpose of the Study:
- To investigate the functional consequences of varying CAR binding affinities and targeted epitopes on CAR-NK cell activation.
- To analyze CAR-NK cell cytolytic synapse formation and antitumor efficacy against AML.
- To understand how CAR affinity influences CAR-NK cell responses in different timeframes and models.
Main Methods:
- Generated NK-92 and primary NK cells expressing AML-specific CARs (26292 or 7G3 targeting CD123) with variant affinities.
- Conducted in vitro binding, activation, and cytotoxicity assays.
- Utilized high-resolution imaging and mouse xenograft models for in vivo evaluation.
Main Results:
- CARs were highly expressed and mediated antigen-specific activation.
- High-affinity CAR-NK cells showed rapid AML cell killing, while low-affinity CAR-NK cells demonstrated superior antigen density discrimination and sustained cytotoxicity.
- Low-affinity CAR-NK cells exhibited enhanced expansion in vivo.
Conclusions:
- CAR-NK cell expression with varying CD123 binding affinities induces antigen-specific activation and cytotoxicity against AML.
- Affinity-dependent functional differences are time-course and scFv/epitope specific.
- Low-affinity CARs may offer advantages for sustained antitumor activity and in vivo expansion.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...

